Autism Spectrum Disorder (ASD)

Total Page:16

File Type:pdf, Size:1020Kb

Autism Spectrum Disorder (ASD) From: [email protected] To: [email protected] Subject: Condition Petition for Thomas Rosenberger Date: Tuesday, December 31, 2019 5:15:54 PM Attachments: Question 1 Autism.pdf Question 2 Autism.pdf Question 3 Autism.pdf Question 5 Autism.pdf This message was sent from the Condition page on medicalmarijuana.ohio.gov. Box was check regarding file size being too large to upload. Action needed! Name: Thomas Rosenberger Address: 815 Grandview Ave Suite 400, Columbus, OH, 43215 Phone: (614) 706-3782 Email: [email protected] Specific Disease or Condition: Autism Spectrum Disorder (ASD) Information from experts who specialize in the disease or condition. See attached file Question 1 Autism.pdf Relevant medical or scientific evidence pertaining to the disease or condition. See attached file Question 2 Autism.pdf Consideration of whether conventional medical therapies are insufficient to treat or alleviate the disease or condition. See attached file Question 3 Autism.pdf Evidence supporting the use of medical marijuana to treat or alleviate the disease or condition, including journal articles, peer-reviewed studies, and other types of medical or scientific documentation. File larger than 3MB Letters of support provided by physicians with knowledge of the disease or condition. This may include a letter provided by the physician treating the petitioner, if applicable. See attached file Question 5 Autism.pdf Question 1 Information from experts who specialize in the disease or condition Contents Overview – 3 Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014 – 4 Overview Autism spectrum disorder (ASD) is characterized by challenges with social skills, repetitive behaviors, speech and nonverbal communication. The conditions impact varies wildly, with some patients functioning at a high level with little intervention, while other patients are never able to live independently. We still know little about the cause of ASD, but evidence suggests the condition is on the rise. The Autism and Developmental Disabilities Monitoring Network compiles reports like the one attached below regularly regarding the rate of ASD. In 2014, they estimated 16.8 per 1,000 children aged 8 have ASD. With the rate of ASD on the rise it is more important than ever that we provide physicians the tools they need to treat this condition based on their assessment of an individual patient. The evidence provided within this application shows clearly that medical marijuana can be an effective treatment for some individuals with ASD. Morbidity and Mortality Weekly Report Surveillance Summaries / Vol. 67 / No. 6 April 27, 2018 Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Surveillance Summaries CONTENTS Introduction ............................................................................................................2 Methods ....................................................................................................................4 Results .......................................................................................................................9 Discussion ............................................................................................................. 12 Limitations ............................................................................................................ 15 Future Surveillance Directions....................................................................... 15 Conclusion ............................................................................................................ 15 References ............................................................................................................. 16 The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027. Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR Surveill Summ 2018;67(No. SS-#):[inclusive page numbers]. Centers for Disease Control and Prevention Robert R. Redfield, MD, Director Anne Schuchat, MD, Principal Deputy Director Leslie Dauphin, PhD, Acting Associate Director for Science Joanne Cono, MD, ScM, Director, Office of Science Quality Chesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services Michael F. Iademarco, MD, MPH, Director, Center for Surveillance, Epidemiology, and Laboratory Services MMWR Editorial and Production Staff (Serials) Charlotte K. Kent, PhD, MPH, Acting Editor in Chief, Executive Editor Martha F. Boyd, Lead Visual Information Specialist Christine G. Casey, MD, Editor Maureen A. Leahy, Julia C. Martinroe, Mary Dott, MD, MPH, Online Editor Stephen R. Spriggs, Tong Yang, Teresa F. Rutledge, Managing Editor Visual Information Specialists David C. Johnson, Lead Technical Writer-Editor Quang M. Doan, MBA, Phyllis H. King, Jeffrey D. Sokolow, MA, Project Editor Paul D. Maitland, Terraye M. Starr, Moua Yang, Information Technology Specialists MMWR Editorial Board Timothy F. Jones, MD, Chairman William E. Halperin, MD, DrPH, MPH Jeff Niederdeppe, PhD Matthew L. Boulton, MD, MPH King K. Holmes, MD, PhD Patricia Quinlisk, MD, MPH Virginia A. Caine, MD Robin Ikeda, MD, MPH Patrick L. Remington, MD, MPH Katherine Lyon Daniel, PhD Rima F. Khabbaz, MD Carlos Roig, MS, MA Jonathan E. Fielding, MD, MPH, MBA Phyllis Meadows, PhD, MSN, RN William L. Roper, MD, MPH David W. Fleming, MD Jewel Mullen, MD, MPH, MPA William Schaffner, MD Surveillance Summaries Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014 Jon Baio, EdS1; Lisa Wiggins, PhD1; Deborah L. Christensen, PhD1; Matthew J Maenner, PhD1, Julie Daniels, PhD2; Zachary Warren, PhD3; Margaret Kurzius-Spencer, PhD4; Walter Zahorodny, PhD5; Cordelia Robinson Rosenberg, PhD6; Tiffany White, PhD7; Maureen S. Durkin, PhD8; Pamela Imm, MS8; Loizos Nikolaou, MPH1,9; Marshalyn Yeargin-Allsopp, MD1; Li-Ching Lee, PhD10; Rebecca Harrington, PhD10; Maya Lopez, MD11; Robert T. Fitzgerald, PhD12; Amy Hewitt, PhD13; Sydney Pettygrove, PhD4; John N. Constantino, MD12; Alison Vehorn, MS3; Josephine Shenouda, MS5; Jennifer Hall-Lande, PhD13; Kim Van Naarden Braun, PhD1; Nicole F. Dowling, PhD1 1National Center on Birth Defects and Developmental Disabilities, CDC; 2University of North Carolina, Chapel Hill; 3Vanderbilt University Medical Center, Nashville, Tennessee; 4University of Arizona, Tucson; 5Rutgers University, Newark, New Jersey; 6University of Colorado School of Medicine at the Anschutz Medical Campus; 7Colorado Department of Public Health and Environment, Denver; 8University of Wisconsin, Madison; 9Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee; 10Johns Hopkins University, Baltimore, Maryland; 11University of Arkansas for Medical Sciences, Little Rock; 12Washington University in St. Louis, Missouri; 13University of Minnesota, Minneapolis Abstract Problem/Condition: Autism spectrum disorder (ASD). Period Covered: 2014. Description of System: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance system that provides estimates of the prevalence of autism spectrum disorder (ASD) among children aged 8 years whose parents or guardians reside within 11 ADDM sites in the United States (Arizona, Arkansas, Colorado, Georgia, Maryland, Minnesota, Missouri, New Jersey, North Carolina, Tennessee, and Wisconsin). ADDM surveillance is conducted in two phases. The first phase involves review and abstraction of comprehensive evaluations that were completed by professional service providers in the community. Staff completing record review and abstraction receive extensive training and supervision and are evaluated according to strict reliability standards to certify effective initial training, identify ongoing training needs, and ensure adherence to the prescribed methodology. Record review and abstraction occurs in a variety of data sources ranging from general pediatric health clinics to specialized programs serving children with developmental disabilities. In addition, most of the ADDM sites also review records for children who have received special education services in public schools. In the second phase of the study, all abstracted information is reviewed systematically by experienced clinicians to determine ASD case status. A child is considered to meet the surveillance case definition for ASD if he or she displays behaviors, as described on one or more comprehensive evaluations completed by community-based professional providers, consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for autistic disorder; pervasive developmental disorder–not otherwise specified (PDD-NOS, including atypical autism); or Asperger disorder. This report provides updated ASD prevalence estimates for children aged 8 years during the 2014 surveillance year, on the basis of DSM-IV-TR criteria, and describes characteristics of the population of children with ASD. In 2013, the American Psychiatric Association published the
Recommended publications
  • Promising Role for Gc-MAF in Cancer Immunotherapy: from Bench to Bedside
    Caspian J Intern Med 2017; 8(4):228-238 DOI: 10.22088/cjim.8.4.228 Review Article Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside Ehsan Saburi (PhD) 1, 2 Amin Saburi (MD) 3 Mostafa Ghanei (MD) *3 Abstract Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell- mediated immunity. Anticancer medications are administered to inhibit 1. Department of Cancer Research, Nastaran Center for Cancer immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic Prevention, Mashhad, Iran. cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications 2. Department of Molecular can also enhance immune-cell activity against tumors. Such medications show great Medicine, Zanjan University of potential in cancer immunotherapy using natural human mechanisms against neoplasms. Medical Sciences, Zanjan, Iran. 3. Chemical Injuries Research Keywords: Cancer, Immunotherapy, Macrophage activating factor, Gc-MAF, Vitamin D. Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Citation: Saburi E, Saburi A, Ghanei M. Gc-MAF promising role for cancer immunotherapy: From bench to bedside approach. Caspian J Intern Med 2017; 8(4): 228-238. * Correspondence: Mostafa Ghanei, Chemical Injuries Research Center, Baqiyatallah ancer is one of the most frequent and important causes of mortality and morbidity University of Medical Sciences, C Tehran, Iran. in humans. In developed countries, cancer imposes a huge cost in the health system. Although cancer therapy has advanced considerably in recent decades, the cancer mortality rate has continued to rise (1). Available cancer treatments vary and include chemotherapy (mitomysin, cisplatin), radiotherapy and biological-based medications (gene therapy, E-mail: [email protected] RNAi treatment, hormone treatment and immunotherapy) (2-4).
    [Show full text]
  • 2010 Final Program
    Guiding Cancer Immunotherapy / Biological Therapy from Bench to Bedside Final Program 25th Annual Scientific Meeting October 2 – 4, 2010 Washington, D.C. hyatt Regency Washington on Capitol hill www.isbtc.org 2010 Supporters (as of September 21, 2010) AnnuAl MeetinG educAtiOnAl SuPPOrt PrOMOtiOnAl SuPPOrt Platinum Bronze Gold Other Abstract Book Bronze Young Investigator Travel Awards – 2 AnnuAl MeetinG & ASSOciAted PrOGrAMS educAtiOnAl SuPPOrt Gold Silver Center for Cancer Research national Cancer institute Bronze copper Program at a Glance * separate registration required thurSdAy, SePteMBer 30, 2010 location 8:00 am – 5:00 pm symposium on immuno-oncology Biomarkers, 2010 and Beyond: Perspectives from the Masur auditorium on the nih isBtc Biomarkers task Force * Campus 5:00 pm – 8:00 pm Registration open at hyatt Regency Washington on Capitol hill Regency Foyer FridAy, OctOBer 1, 2010 6:30 am – 5:00 pm Registration open Regency Foyer 7:00 am – 8:00 am Continental Breakfast Columbia 8:00 am – 5:00 pm Primer on tumor immunology & Biological therapy of Cancer * Regency a 8:00 am – 5:00 pm Workshop on Monoclonal antibodies in Cancer * Capitol Room, Lobby Level SAturdAy, OctOBer 2, 2010 6:30 am – 6:00 pm Registration open Regency Foyer 7:00 am – 7:45 am Early Career scientists “Meet-the-Expert Breakfasts” * Capitol B, Lobby Level 7:00 am – 7:45 am new Member gathering tBa 7:00 am – 8:00 am Continental Breakfast Columbia 7:50 am – 8:00 am 25th annual Meeting Begins / President’s Welcome Regency a 8:00 am – 8:45 am Richard V. Smalley, MD Memorial Lectureship: James P.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,701.718 B2 Sullivan Et Al
    US0097.01718B2 (12) United States Patent (10) Patent No.: US 9,701.718 B2 Sullivan et al. (45) Date of Patent: Jul. 11, 2017 (54) ADENOVIRUS SEROTYPE 26 AND (56) References Cited SEROTYPE 35 FILOVIRUS VACCNES U.S. PATENT DOCUMENTS (75) Inventors: Nancy J. Sullivan, Kensington, MD 6,852,324 B1* 2/2005 Nabel .................. CO7K 14f005 (US); Gary J. Nabel, Washington, DC 424,199.1 (US); Clement Asiedu, Olney, MD 7,094,598 B2 * 8/2006 Nabel et al. ............... 435/320.1 (US); Cheng Cheng, Rockville, MD 7,635,485 B2* 12/2009 Nabel .................... A61K 39,12 424,199.1 (US); Maria Grazia Pau, Leiden (NL); 7,635,688 B2* 12/2009 Nabel .................. CO7K 14f005 Jaap Goudsmit, Amsterdam (NL) 424.92 7,741,099 B2 6/2010 Havenga et al. (73) Assignees: Janssen Vaccines & Prevention B.V., 8,017,130 B2 * 9/2011 Nabel .................... A61K 39,12 424,199.1 Leiden (NL); THE UNITED STATES 8, 101,739 B2 1/2012 Sullivan et al. OF AMERICA, AS REPRESENTED 8, 106,026 B2 * 1/2012 Nabel .................. CO7K 14f005 BY THE SECRETARY, 424.92 DEPARTMENT OF HEALTH AND 8, 106,027 B2 * 1/2012 Nabel .................. CO7K 14f005 HUMAN SERVICES, THE OFFICE 424.92 OF TECHNOLOGY TRANSFER, 8,124,592 B2 * 2/2012 Nabel .................. CO7K 14f005 NATIONAL INSTITUTE OF 424.92 2004/0259825 A1 12, 2004 Nabel et al. HEALTH, Washington, DC (US) 2005/0196384 A1* 9/2005 Vogels et al. ................ 424.93.2 2006/0148087 A1 7/2006 Nabel et al. (*) Notice: Subject to any disclaimer, the term of this 2008/O1999.39 A1 8/2008 Havenga et al.
    [Show full text]
  • Gcmaf: Our Next-Generation Immunotherapy
    SPONSOR FEATURE SPONSOR FEATURE GcMAF: our next-generation immunotherapy Authors Saisei Mirai, based in Osaka, Japan, is a immunotherapy — such as dendritic cells, Yoshihiro Uto1, Hitoshi Hori1, Kentaro medical organization specializing in cancer autologous lymphocyte-activated killer Kubo2, Masamitsu Ichihashi3, Norihiro immunotherapy. The name Saisei Mirai is (LAK) cells, autologous NK cells, mono- Sakamoto3,4, Martin Mette5, Toshio Inui2,3,5 derived from the Japanese words for regen- clonal antibodies, cancer peptide vaccines, eration and future. It is our mission to cytokines, and biological response modifiers 1 Department of Life System, Institute provide cancer patients with the latest, most (BRM) — is rapidly advancing. However of Technology and Science, Graduate effective treatments while also ensuring the in a clinical setting, the results of cancer School, The University of Tokushima, 2-1 best possible quality of life. Cancer immu- immunotherapy are mixed. Minamijosanjima-cho, Tokushima, Japan. notherapy is the use of the immune system We therefore contend that cancer immu- to reject cancer. In particular, it involves notherapy should be customized to each 2 Saisei Mirai Cell Processing Center, stimulating the patient’s immune system individual patient based on their immune Nature21 Building 3F, 3-34-8 Okubo-cho, to locate and eliminate the cells that are status. We propose our next-generation Gc Moriguchi, Osaka, Japan. cancerous. This is achieved with immune protein-derived macrophage activating fac- cells such as Natural Killer cells (NK cells), tor (GcMAF) as a promising candidate for 3 Kobe Saisei Mirai Clinic, Kobe T Lymphocytes, Dendritic Cells (DC), and a patient-friendly cancer immunotherapy. Commerce Industry and Trade Center macrophages, among others.
    [Show full text]